Biosergen publishes interim report for fourth quarter 2022
Friday, March 31, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the fourth quarter 2022. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q4 2022
| 2022 | 2021 | 2022 | 2021 | |
| TSEK | Oct-Dec | Oct-Dec | Jan-Dec | Jan-Dec |
| Other income | 1.964 | 3.290 | 5.183 | 8.573 |
| Profit/loss before depreciation (EBITDA) | -12.491 | -9.876 | -39.987 | -34.077 |
| Operating profit/loss befor net financials | -12.491 | -9.876 | -39.987 | -34.077 |
| Net financials | 87 | -83 | 109 | -240 |
| Netprofit/loss for the period | -12.432 | -9.959 | -39.906 | -34.318 |
| Earnings per share (SEK) | -0,40 | -0,35 | -1,28 | -1,22 |
Highlights during Q4 2022
- October 4, Biosergen announces the outcome in the rights issue
- December 12, The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005.
Highlights after the period
- January 16, Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial.
- March 13, Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
- March 29, Biosergen provides Phase 2 clinical development strategy update.
The Financial report can be found on our website: https://biosergen.net/investors/filings
Annual Report
The annual report was planned to be published on April 6. It will now be disclosed on May 10 due to the work with the annual report has taken longer time then previously expected.
Biosergen will conveine its Annual General Meeting May 31.